CMPI

Checkmate Pharmaceuticals, Inc.

NASDAQ

Add Alert

CMPI

Checkmate Pharmaceuticals, Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

hedge_fun

04/19/22 2:53 PM

Post #20

Re: #19: @Just-Keep-Trying - How much PROFIT did you make, Dude??? Inspire

Geez, I simply congratulated longs but now.......

I’m being asked to be a motivational speaker.

Amusing

Just-Keep-Trying Terminated

04/19/22 2:26 PM

Post #19

Re: #18: @hedge_fun - Congrats longs. Pop the champagne and.......

How much PROFIT did you make, Dude??? Inspire us!! Heck with the champaigne --- our men need NUMBERS!

hedge_fun

04/19/22 9:15 AM

Post #18

Congrats longs. Pop the champagne and.......

pour me a glass, please.

TheFinalCD PremiumMember

04/19/22 9:10 AM

Post #17

Re: #15: @crudeoil24 - Regeneron to Buy Checkmate Pharmaceuticals for About $250

*CHECKMATE*

Awl416

04/19/22 7:42 AM

Post #16

Congrats

crudeoil24 PremiumMember

04/19/22 7:36 AM

Post #15

Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million >REGN CMPI
7:17 am ET April 19, 2022 (Dow Jones) Print

By Colin Kellaher

Regeneron Pharmaceuticals Inc. on Tuesday said it agreed to buy clinical-stage biopharmaceutical company Checkmate Pharmaceuticals Inc. for about $250 million in a deal that bolsters Regeneron's portfolio of diverse and combinable immuno-oncology candidates.

Regeneron said it will pay $10.50 a share in cash for Checkmate, more than four times Monday's closing price of $2.41 for the Cambridge, Mass., company.

Regeneron said Checkmate's lead investigational asset, vidutolimod, is currently being studied in combination with other agents for melanoma, nonmelanoma skin cancers, and head and neck cancer.

The Tarrytown, N.Y., biotechnology company said it expects to complete the acquisition around the middle of the year.

Trading in shares of Checkmate was halted premarket Tuesday.

BlazingStocks PremiumMember

06/29/21 11:27 AM

Post #14

$CMPI had it's highest volume in a year, let's see what happens next. We could be getting an update soon.

BlazingStocks PremiumMember

06/22/21 2:33 PM

Post #13

Great $CMPI volume heading into Power Hour!

BlazingStocks PremiumMember

06/21/21 2:52 PM

Post #12

$CMPI posted an 8-k pertaining to the Shareholders Meeting...

https://last10k.com/sec-filings/cmpi/0001193125-21-194290.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=cmpi

BlazingStocks PremiumMember

06/16/21 10:51 AM

Post #11

Re: #8: @wildstock - $CMPI Barchart opinion looks oversold see here - https://www.barchart.com/stocks

$CMPI trading over 25% of its 10-day average volume in the first 80 minutes!

BlazingStocks PremiumMember

06/15/21 3:51 PM

Post #10

Re: #7: @wildstock - $CMPI daily chart poised for a breakout soon https://stockcharts.com/h-sc/ui?s=C

Let's see if the $CMPI chart can make a reversal and then continue its plot upwards...

wildstock

06/15/21 11:52 AM

Post #9

Re: #8: @wildstock - $CMPI Barchart opinion looks oversold see here - https://www.barchart.com/stocks

$CMPI Strong support level @ 6$ https://www.barchart.com/stocks/quotes/CMPI/cheat-sheet

wildstock

06/15/21 11:51 AM

Post #8

$CMPI Barchart opinion looks oversold see here - https://www.barchart.com/stocks/quotes/CMPI/opinion

wildstock

06/15/21 11:50 AM

Post #7

$CMPI daily chart poised for a breakout soon https://stockcharts.com/h-sc/ui?s=CMPI

BlazingStocks PremiumMember

06/11/21 10:38 AM

Post #6

$CMPI trading at 25% of its 10-day average volume...in the first hour!

BlazingStocks PremiumMember

06/09/21 10:15 AM

Post #5

$CMPI has a 10-day average volume of almost 26k but has been trading at that level or higher for the past month.

BlazingStocks PremiumMember

06/08/21 9:55 AM

Post #4

$CMPI News May 13, 2021

Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress
https://finance.yahoo.com/news/checkmate-pharmaceuticals-reports-first-quarter-201000665.html

jedijazz

06/07/21 1:35 PM

Post #3

$CMPI Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo

https://www.nasdaq.com/articles/checkmate-pharmaceuticals-releases-clinical-data-for-vidutolimod-and-pembrolizumab-combo

wildstock

06/07/21 1:11 PM

Post #2

$CMPI Recent News : Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
https://finance.yahoo.com/news/checkmate-pharmaceuticals-present-jefferies-2021-203000628.html

wildstock

06/07/21 1:10 PM

Post #1

$CMPI Gallery View https://stockcharts.com/freecharts/gallery.html?CMPI

Checkmate Pharmaceuticals, Inc. (CMPI)

Followers	0	Posters	8
Posts (Today)	0	Posts (Total)	20
Created	06/07/21	Type	Free
Moderators

Checkmate Pharmaceuticals, Inc.

Corporate Profile

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate’s product candidate, vidutolimod (CMP-001), is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Checkmate’s goal is to leverage its proprietary technology to discover, develop and commercialize transformative treatments to fight cancer.

Latest Corporate Presentation

May 10, 2021

Checkmate Pharmaceuticals Corporate Overview – May 2021

Company Info:

Company Overview:

More on ImmunoTherapy:

Board Of Directors:

Press Releases:

Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

May 20, 2021

Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress

May 13, 2021

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)

May 10, 2021

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma

May 04, 2021

Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

Apr 28, 2021

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial

Apr 19, 2021

Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting

Apr 11, 2021

Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress

Mar 29, 2021

Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2021

Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

Jan 04, 2021

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Checkmate disavows any obligation to update the information contained in such press releases after the date of their issuance.

$CMPI Simple Moving Average DAILY CHART

DISCLAIMER:

Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.